
|Articles|April 18, 2019
The Era of PARP Inhibition in Cancer Management - Patient Selection and Deciding When to Use in Treatment
https://www.pharmacytimes.org/on-demand/the-era-of-parp-inhibition-in-cancer-management-patient-selection-and-deciding-when-to-use-in-treatment-enduring
Advertisement
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Emerging Data Suggest Survodutide Targets Liver Fat More Rapidly Than Weight Loss: Lee Kaplan, MD, PhD
2
Survodutide Normalizes Liver Fat in 61% of Patients With MASLD in Phase 3 Trial: Lee Kaplan, MD, PhD
3
Bridging Science and Reality in Diabetes Care
4
Nutrition in Pregnancy May Shape Metabolic Health After Delivery
5




